Day 4 Program

Poster Session 5

Day 4: December 11, 2026

12:30 PM–2:00 PM CST

Exhibit Hall

Session Details

P5-1-01

De Novo Melasma and Vitiligo-Like Leucoderma During Uninterrupted Ribociclib-Based Therapy: Concurrent Opposing PigmentaryPhenomena in Metastatic Breast Cancer

Khaled W Sadek, Hamad Medical Corporation, Doha, Qatar

P5-1-02

Cutaneous Toxicities Associated with CDK4/6 Inhibitors in Patients with Hormone Receptor-Positive (HR+), HER2-Negative Breast Cancer: A Case Series from a Tertiary Center in Saudi Arabia

Sharif KULLAB, King Saud University MEdical City (KSUMC) Riyadh, Riyadh, Saudi Arabia

P5-1-03

A rare case of left giant phyllodes tumor with NICTH and synchronous right invasive ductal cancer

Pavani Peddi, Holy Name Medical Center, Teaneck, NJ

P5-1-04

Concurrent Locally Advanced Breast Cancer and Metastatic Undifferentiated PEComa treated with mTOR inhibitor plus aromatase inhibitor

Aslihan Yerlikaya, Montefiore-Einstein Comprehensive Cancer Center, Bronx, NY

P5-1-05

Clear Cell Carcinoma of the Breast: A Single-Institution Case Series of a Histological Rarity

Melanie Shpigel, UPMC Central Pennsylvania, Harrisburg, PA

P5-1-06

The Impact of Prior Chest Wall Burns on Sentinel Lymph Node Mapping in Breast Cancer: A Case Report

Andrea Smith, UTHSC Nashville, Nashville, TN

P5-1-07

Emergence of endocrine refractory breast cancer on adjuvant abemaciclib with 18F-FES PET and IHC discordance

Jasmine Haoying Zhang, Rush University Medical Center, Chicago, IL

P5-1-08

Hypercalcemia of malignancy as the initial presentation of metastatic malignant phyllodes tumor: a case report of an exceptionally rare and aggressive clinical course

Amanda Dias, Hospital Nove de Julho, São Paulo, Brazil

P5-1-09

Breast epithelial-myoepithelial carcinoma: a diagnostic and therapeutic challenge in a rare biphasic malignancy

Larissa Martins de Brito Moraes, Hospital do Andaraí, Rio de Janeiro, Brazil

P5-1-10

Metastatic lung adenocarcinoma presenting with a breast mass: a rare diagnostic challenge

Stephanie Adel Haddad, UT Health San Antonio/Mays Cancer Center, San Antonio, TX

P5-1-11

Ductal Carcinoma in Situ (DCIS) within Giant Fibroadenoma with Additional Contralateral Foci of DCIS: A Case Report

Sophia Liu, Stony Brook University Hospital, Stony Brook, NY

P5-1-12

Mammaprint Assay Classification of HER2 Cancers: Navigating Complete Response discordance in Practice for Early Stage Breast Cancer

Allison Hultgren, LSU Health Shreveport, Shreveport, LA

P5-1-13

Rapidly expanding recurrent phyllodes tumor of the breast with high-grade sarcomatous transformation and hemorrhage requiring transfusion; A rare case report

Gladys Bruyninx, University of Montreal, Montreal, QC, Canada

P5-1-14

Erythema nodosum as a possible paraneoplastic manifestation preceding disease progression in breast cancer: a case report

Amanda Araújo Dias, Hospital Nove de Julho, São Paulo, Brazil

P5-1-15

Primary Mammary-Type Adenocarcinoma of the Vagina Treated on a Triple-Negative Breast Cancer Paradigm in a Patient with Low-Grade Serous Carcinoma of the Peritoneum

Karishma Vijay Rupani, Mount Sinai Tisch Cancer Center, New York, NY

P5-1-16

A Heavily Pretreated Patient with Metastatic Breast Cancer: An Exceptional Responder Case Report

Rachel Seng, American University of Caribbean, St. Maarten, Cupecoy, Saint Martin

P5-1-17

Antibody-drug conjugate and immunotherapy combination yields objective response in a patient with metastatic, triple-negative HRAS and PIK3CA mutant malignant adenomyoepithelioma of the breast

Priyal Agarwal, Medical University of South Carolina, Charleston, SC

P5-1-18

Adenoid Cystic Carcinoma of the Breast: metastatic disease treated with Lenvatinib

Stephanie Purkat Lindauer, Arizona Center for Cancer Care/Honor Health Cancer Care, Phoenix, AZ

P5-1-19

Paraneoplastic Encephalitis in a Patient with Metastatic Hormone Receptor Positive Breast Cancer

Katrina Fisher, UT Health San Antonio, San Antonio, TX

P5-1-20

Mimicking melanoma: A case of metaplastic triple negative breast cancer with melanocytic differentiation

Briana To, The Ohio State University, Columbus, OH

P5-1-22

Spontaneous Tumor Lysis Syndrome Preceding Any Anticancer Therapy in a Patient with HER2-Positive Metastatic Breast Cancer and Extensive Hepatic Involvement

Khaled W Sadek, Hamad Medical Corporation, Doha, Qatar

P5-1-23

Primary Osteosarcoma of the Breast: a case report

Rosemar Macedo Sousa Rahal, Federal University of Goias, School of Medicine, Goiania – GO, Brazil

P5-1-24

Rapid resolution of malignant TNBC pericardial effusion with datopotamab deruxtecan

Kenna Noel Koehler, The Ohio State University James Comprehensive Cancer Center, Columbus, OH

P5-1-25

Superior vena cava syndrome secondary to an immune-mediated non necrotizing histiocytic reaction

Rosa M Anaya-Jiménez, Médica Sur, Mexico City, Mexico

P5-1-26

The Ghost of Radiation Past: A Biopsy-Proven case of Ribociclib-Triggered Radiation Recall Dermatitis

Ratika Dogra, Henry ford Health, Detroit, MI

P5-1-27

A tale of two patients: Durable complete remissions exceeding 7 and 10 years with sequential immune checkpoint blockade and PARP inhibition in metastatic triple-negative breast cancer

Jacob Lee, University of California, Irvine, Orange, CA

P5-1-28

Late Recurrence Without Locoregional Disease in Male Breast Cancer – A Case Report Exploring Survivorship Surveillance and Outcomes

Shivangi Sharma, Northwell Health Danbury Hospital, Danbury, CT

P5-1-29

[<sup>18</sup>F] fluoroestradiol pet reveals biopsy-proven occult distant metastasis in presumed localized invasive lobular carcinoma

Sarah Adilla Shaker, UT Health Houston, Houston, TX

P5-1-30

Spatial and Temporal Receptor Heterogeneity in HER2-Positive Breast Cancer With Bilateral Ovarian Metastases

Regina Moreno-Lopez, Hospital Médica Sur, Ciudad de México, Mexico

P5-2-01

Well Differentiated Retroperitoneal Liposarcoma in a BRCA2 Carrier: A Novel Association

Roma Patil, NYC H+H / Metropolitan Hospital Centre, New York, NY

P5-2-02

Amyloid in Disguise: Localized AL (Lambda)-Type Breast Amyloidosis Uncovered by Screening Mammography

Shobha Mandal, Reading Hospital Tower Health, West Reading, PA

P5-2-03

Nab-paclitaxel-induced bilateral Bell’s palsy in metastatic HR-positive breast cancer: a rare neurologic adverse event

Michael Kong, The Ohio State University, Columbus, OH

P5-2-04

Interrupted Immunotherapy Due to Recurrent Pregnancy in Metaplastic Triple Negative Breast Cancer: A Case Report of Compounding Therapeutic Challenges

Roma Patil, NYC H+H / Metropolitan Hospital Centre, New York, NY

P5-2-05

Idiopathic Intracranial Hypertension like Presentation of Isolated Leptomeningeal Metastasis from Invasive Lobular Breast Carcinoma During Adjuvant Abemaciclib

Khaled W. Sadek, Hamad Medical Corporation, Doha, Qatar

P5-2-06

Exceptional Response to Olaparib in a Young African American Woman with PALB2-Mutated Breast Cancer: From Visceral Crisis to Near-Complete Resolution of Metastatic Disease

Dali Edwards, Medical University of South Carolina, Charleston, SC

P5-2-07

Synchronous receptor discordance between a HER2-positive breast primary and triple-negative axillary metastasis: implications for neoadjuvant treatment planning

Makenna Smith, Texas Tech University Health Sciences Center, Lubbock, TX

P5-2-08

Unilateral Non-CF Bronchiectasis and Mycobacterium Avium Complex Infection After Post-Lumpectomy Radiation for Invasive Ductal Carcinoma in a Patient Heterozygous for CFTR TG12T5: A Case Report

Darshi Shah, Yale-New Haven Hospital, New Haven, NY

P5-2-09

Counseling Beyond Ovarian Cancer: A BRIP1 Pathogenic Variant in a Breast Cancer Predominant Family History

Bharat Kumar Peddinani, UTRGV, Harlingen, TX

P5-2-10

Navigating gender-affirming testosterone therapy during hormone-positive breast cancer treatment: A case report

Sarisha Mahajan, University Hospitals/Case Western Reserve School of Medicine, Cleveland, OH

P5-2-11

Pulsed Electric Field (PEF) treatment of metastatic triple negative breast cancer concurrently with chemo-immunotherapy: Oligometastatic disease to remission

Stephanie Purkat Lindauer, Arizona Center for Cancer Care/HonorHealth Cancer Care, Scottsdale, AZ

P5-2-12

Pure Male Breast IMPC with HER2 Discordance by Polar Reversal: A Case Report

Feng Zhao, The First Affiliated Hospital of Anhui University of Science and Technology, Huainan, China

P5-2-13

Correlation of Circulating Tumor DNA with Intracranial Metastatic Breast Cancer

Kundan Joshi, Rush University Medical Center, Chicago, IL

P5-2-14

When Rarity Meets Collaboration: Multidisciplinary Community Care in Young Male Breast Cancer

Mian Arsam Haroon, Bayhealth Medical Center, Dover, DE

P5-2-15

Durable Intracranial Response to Trastuzumab Deruxtecan Following Whole Brain Radiotherapy in a Patient with HER2 Positive Metastatic Breast Cancer and Chronic HIV and Hepatitis B Infection: A Case Report

Dilrukshika Kumarihami, Castle Hill Hospital, Hull University Teaching Hospital NHS Trust, Hull, United Kingdom

P5-2-16

Pseudocirrhosis Associated with Treatment Response to First-Line Trastuzumab, Pertuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer: a case report

Lara Gonçalves Sette, Instituto D'Or de Pesquisa e Ensino, São Paulo, Brazil

P5-2-17

Exceptional durable response to combined endocrine therapy, CDK4/6 inhibition, and concurrent intrathecal chemotherapy in HR+ breast cancer with leptomeningeal disease

Elysa Cortez, The University of Texas Health and Science Center at Houston, Houston, TX

P5-2-18

Clinicopathological Features and Prognosis in Patients with Glycogen-Rich Clear Cell Breast Carcinoma

Izzet Dogan, Acibadem Healthcare Group, Istanbul, Turkey

P5-2-19

Plasma ctDNA Profiling in Taiwanese Metastatic Breast Cancer Reveals Guideline-Relevant Alterations and Methylation-Informed Clinical Subtype Classification

Wen-Ling Kuo, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan

P5-2-20

Does Young Age Justify Aggressive Surgery? Long-Term Locoregional Recurrence in Young Asian Women with Breast Cancer

Kyung-Hwak Yoon, Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of

P5-2-21

Best of Both Worlds? Real-world analysis of combining dose-dense anthracycline-based chemotherapy with the KEYNOTE-522 pembrolizumab regimenin early triple-negative breast cancer

Meike Baur, University Hospital Schleswig-Holstein, Campus Luebeck; Universitiy of Luebeck, Luebeck, Germany

P5-2-22

Redefining the Present: Is the Era of Adjuvant T-DM1 Over?

Alejandro Falcón-González, Hospital Universitario Virgen del Rocío, Seville, Spain

P5-2-23

Iron Deficiency Anemia and Cardiovascular Outcomes in Breast Cancer Patients with Heart Failure with Reduced Ejection Fraction: A Real-World Analysis

Niyati Shambhubhai Avaiya, SUNY Upstate Medical University, Syracuse, NY

P5-2-24

Precision Rather Than Age: A Decade of Change in Breast Cancer Treatment Among Women Aged ≥70 Years

Maria Jose Martinez Suazo, Clinica Alemana, Santiago, Chile

P5-2-26

Advanced Breast Cancer in Chile: Clinical Characterization, Treatment Patterns, and Survival in a Multicenter Real World Registry

Francisco Acevedo, Pontificia Universidad Católica de Chile, Santiago, Chile

P5-2-27

Fertility in young patients with breast cancer: Evolution of reproductive counseling and fertility preservation, an invisibilized issue

Marcela Amar, Clinica Davila, Santiago, Chile

P5-2-28

Who cannot wait? Time to treatment initiation according to tumor biology in young women with her2-negative breast cancer: a brazilian real-world cohort

Alessandra Notari, Federal University of Health Sciences of Porto Alegre, Porto Alegre, Brazil

P5-2-29

Integrated genomic and epigenomic profiling of circulating tumor DNA after CDK4/6 inhibitor progression in HR+/HER2- metastatic breast cancer receiving cytotoxic therapy

Letizia Pontolillo, Weill Cornell Medicine, New York, NY

P5-2-30

Glow-breast (glucagon-like peptide-1 receptor agonists outcomes in women with breast cancer): a two-phase cohort study of glp-1 receptor agonist use during adjuvant endocrine therapy

Rafael Moura Castro, AC CAMARGO CANCER CENTER, SAO PAULO-SP, Brazil

P5-3-01

Patterns of distant recurrence after neoadjuvant therapy in stage I-III triple-negative breast cancer: A real-world cohort

Stephanie Rice, UTSW, Dallas, TX

P5-3-02

Lumina-latam: clinical and therapeutic patterns in early HR-positive/HER2-negative breast cancer among latin american women: a multicenter retrospective study

Henry L Gomez Moreno, Oncosalud AUNA, Lima`, Peru

P5-3-03

Real-world overall survival with trastuzumab deruxtecan in patients with HER2-low metastatic breast cancer and CNS/brain metastases

Kriti Ahuja, Wertheim Cancer Institute, Baptist Health South Florida, Miami, FL

P5-3-04

Single-centre data of Ribociclib-use in metastatic breast cancer

Lieselotte Rega, University Hospitals Leuven, Leuven, Belgium

P5-3-05

Cumulative incidence and predictors of CNS metastases among patients with HER2+ metastatic breast cancer receiving trastuzumab deruxtecan

Reshma Mahtani, Wertheim Cancer Institute, Baptist Health South Florida, Miami, FL

P5-3-06

Multicentre Real-World Data of an Asia-Manufactured US FDA-Cleared Scalp Cooling System for Prevention of Chemotherapy-Induced Alopecia: Outcomes and toxicities from Three Indian Cancer Centers

Akhil Kapoor, Tata Memorial Centre (MPMMCC), Varanasi, India

P5-3-07

From Insight to Impact: A Strategic Action Plan for Metastatic Breast Cancer

Diego Armando Pedroza, Baylor College of Medicine, Houston, TX

P5-3-08

Real-world experience with CDK4/6 inhibitors in male hormone receptor-positive/HER2-negative breast cancer: safety and treatment patterns from a Brazilian multicenter cohort

Juliana Mattos, Hospital Nove de Julho, São Paulo, Brazil

P5-3-09

Pre-treatment Neutrophil-to-Lymphocyte Ratio is Associated with Clinical Nodal Burden but Does Not Predict Disease-Free Survival in Non-Metastatic Breast Cancer: A Retrospective 107-Patient Cohort Study from South India.

Nachiketh Rao, Advocate Illinois Masonic Medical Center, Chicago, IL

P5-3-10

Characterizing documented reasons for breast cancer treatment discontinuation and switching using longitudinal clinical notes and linked NorstellaLinQ Electronic Health Records (EHR), Clinical Notes, and Claims Real-World Data

Allison Perry, Norstella, New York, NY

P5-3-11

Racial Differences in Cardiometabolic Health and Treatment Delivery in Early-Stage Triple-Negative Breast Cancer

Jasmin Hundal, Emory University, Atlanta, GA

P5-3-12

Real-world use and effectiveness of ribociclib in HR-positive/HER2-negative advanced breast cancer at a Peruvian public cancer center

Guillermo Valencia, Instituto Nacional de Enfermedades Neoplásicas (INEN), Lima, Peru

P5-3-13

Real world safety and false negative rates of sentinel lymph node biopsy using only patent blue after neoadjuvant chemotherapy: a two center, multi-institutional cohort (2017 2025)

Oscar Antonio Niño de Guzman Luizaga, “Niño de Guzmán” Gynecology Center, Cochabamba, Bolivia, Plurinational State of

P5-3-14

Impact of Pre-existing Chronic Liver Disease on Survival and Healthcare Utilization in Patients with Metastatic Breast Cancer: A Propensity Score-Matched Real-World Cohort Study

TingAn Lin, Johns Hopkins Hospital, Baltimore, MD

P5-3-15

Early Vulnerability Following Sacituzumab Govitecan in Adults Aged >75 Years: A Real-World Propensity-Matched Analysis in a Geriatric Population With Metastatic Breast Cancer</b>

Bibek Shrestha, University of Toledo Medical Center, Toledo, OH

P5-3-16

Real-world treatment patterns in patients with high-risk HER2+ eBC in the United States

Marvin Nguyen, Daiichi Sankyo, Inc., Basking Ridge, NJ

P5-3-17

From BRCA Testing to Family Centered Cancer Prevention: Real World Implementation of an Integrated Molecular and Hereditary Cancer Pathway

LAURA ZAVALLONE, OSPEDALE DEGLI INFERMI, BIELLA, Italy

P5-3-18

Central nervous system (CNS) relapse after pathological complete response (pCR) in HER2-positive early breast cancer (eBC): a competing-risk analysis from the international PEARL-HER2 cohort

Soraia Lobo-Martins, Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, Brussels, Belgium

P5-3-20

Real-world effectiveness, dose intensity, and prognostic factors of trastuzumab deruxtecan in HER2+ and HER2-low metastatic breast cancer

Joyce Habib, Fox Chase Cancer Center, Philadelphia, PA

P5-3-21

Trop-2-directed antibody-drug conjugate monotherapy versus combination therapy in HER2-negative advanced breast cancer: a multicenter real-world study

Bin Shao, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China

P5-3-22

The Post-CDK4/6 Inhibitors Clinical Cliff: Real-World Survival Outcomes and the Impact of the Sequencing Gap in HR+/HER2- Metastatic Breast Cancer

Hikmat Abdel-Razeq, King Hussein Cancer Center, Amman, Jordan

P5-3-23

Real-world dose-escalation patterns and tolerability of neratinib as extended adjuvant therapy in Chinese patients with HER2-positive intermediate- or high-risk early breast cancer: a multicenter preliminary analysis

Yingying Xu, The First Hospital of China Medical University, Shenyang, China

P5-3-24

Clinical Outcomes of TROP2-Targeting Antibody-Drug Conjugates in HER2 negative Metastatic Breast Cancer: A Real-World Single-Institution Study

David Lin, Cedars-Sinai Medical Center, Los Angeles, CA

P5-3-25

Pre-existing Liver Disease and Hepatic Metastasis in Breast Cancer: A Retrospective Cohort Study

Neel Sharma, UT Southwestern Medical Center, Dallas, TX

P5-3-26

Temporal trends in advanced-stage breast cancer among women in Brazil and their correlation with treatment volume and approved expenditures: a real-world evidence time-series study

Isabella Figueiredo, HCOR, Sao Paulo, Brazil, Sao Paulo, Brazil

P5-3-27

Real-world treatment outcomes with trastuzumab deruxtecan, ado-trastuzumab emtansine, and tucatinib-based regimens in HER2+ metastatic breast cancer

David Lembersky, Johns Hopkins Hospital, Baltimore, MD

P5-3-28

Prognostic Role of TP53 and PIK3CA Mutations in Metastatic HR-Positive/HER2-Negative Breast Cancer:A Multicenter Real-World Genomic Study

Derya Kivrak Salim, University of Health Sciences, Antalya Training and Research Hospital, Antalya, Turkey

P5-3-29

Clinical and Biological Profile of Breast Cancer in Women Younger Than 40 Years at a Referral Center in Northeastern Mexico

Analaura Del Rivero-Morfin, UNEME DEDICAM, Guadalupe, Nuevo Leon, Mexico

P5-3-30

Role of Chemotherapy in Local Regional Recurrence A Real-World Analysis at a Major Cancer Center

Catalin Dragomirescu, Cleveland Clinic Foundation, Cleveland, OH

P5-5-01

Real-world treatment patterns, pathologic response, and recurrence in early-stage breast cancer stratified by molecular subtype: an LLM-extracted longitudinal multi-source EHR dataset

Madhuri Paul, NeoGenomics Laboratories, Aliso Viejo, CA

P5-5-02

Clinical and Molecular Features Associated with Central Nervous System (CNS) Involvement in Metastatic Breast Cancer: A Longitudinal Institutional Registry Analysis

Stephanie Rice, UTSW, Dallas, TX

P5-5-03

Real-world tolerability and treatment persistence of cdk4/6 inhibitors in older adults with advanced breast cancer and baseline malnutrition- a trinetx database analysis

Vaishali Deenadayalan, Roswell Park Comprehensive Cancer Center, Buffalo, NY

P5-5-04

Real-world survival and treatment patterns with sacituzumab govitecan in HER2-negative metastatic breast cancer with CNS/brain metastases

Delia Guaqueta, Baptist Health Wertheim Cancer Institute, Kendall, FL

P5-5-05

Breast cancer during pregnancy and the postpartum period: clinicopathological features and outcomes from the multicenter CEBCC-01 study

Milos Holanek, Masaryk Memorial Cancer Institute and Faculty of Medicine, Masaryk University, Brno, Czech Republic

P5-5-06

Adherence to Geriatric Oncology Treatment Recommendations in Older Adults With Breast Cancer: A Single-Center Experience From Mexico

Abigail Samayoa Mateos Soria, Instituto Nacional de Cancerologia, Ciudad de México, Mexico

P5-5-07

Real-world impact of pembrolizumab added to nab-paclitaxel, carboplatin and epirubicin-cyclophosphamide in early triple negative breast cancer.

Rocío Pérez Velasco, Hospital Universitario Virgen del Rocío, Seville, Spain

P5-5-08

Real-world outcomes of sequential antibody-drug conjugate therapy in HR+/HER2- and triple negative metastatic breast cancer

Casey Lee, Cedars-Sinai Medical Center, Los Angeles, CA

P5-5-09

Transportability and Potential Clinical Utility of Survival Prediction Models for Metastatic Breast Cancer Across 14 U.S. Institutions

Asal Pilehvari, University of Virginia, Charlottesville, VA

P5-5-10

Real-world treatment patterns and characteristics of patients with HER2-negative or -low metastatic breast cancer initiating trastuzumab deruxtecan, or not, after progression on endocrine therapy in the US

Reva K Basho, Ellison Medical Institute, Los Angeles, CA

P5-5-11

Real world data on dose modification and discontinuation on all three CDK 4/6 inhibitors among a community hospital based multi-racial cohort

Tianyu Li, Maimonides Cancer Center, Brooklyn, NY

P5-5-12

Body Weight and Tolerability of Trastuzumab Deruxtecan in Breast Cancer: Real-World Evidence From TriNetX

Isabella Figueiredo, HCOR, Sao Paulo, Brazil

P5-5-13

Real-world chemotherapy de-escalation using the 21-gene recurrence score across premenopausal, postmenopausal, and elderly Japanese patients with HR+/HER2− early breast cancer

Miki Yamada, National Cancer Center Hospital East, Kashiwa-city, Chiba, Japan

P5-5-14

Outcomes after locoregional recurrence of invasive lobular carcinoma: a single-health-system registry analysis

Abhinav Anand Vayal Veettil, Cleveland Clinic Foundation, Cleveland, OH

P5-5-15

Serial 18F-fluoroestradiol positron emission tomography/computed tomography (FES PET/CT) in invasive lobular carcinoma: clinical utility and disparities in utilization

Loren Alyssa Cagle, Emory University, Atlanta, GA

P5-5-17

Treatment Timing and Contemporary Oncologic Outcomes in Breast Cancer Diagnosed During Pregnancy: A Real-World Institutional Cohort

Stephanie Rice, UTSW, Dallas, TX

P5-5-18

Correlation between prior treatments on CDK4/6 Inhibitors Initiation and Disability-Adjusted Life Years in Hormone receptor-positive metastatic breast cancer

Joselyn Canelos-Moreno, SOLCA, GUAYAQUIL, Ecuador

P5-5-19

Epidemiology and prospective real-world effectiveness of trastuzumab deruxtecan and other therapies in HR-positive, HER2-low metastatic breast cancer: results of the SHERLOC study in Greece

Rozalia Michalea, AstraZeneca Greece, Athens, Greece

P5-5-20

Investing in Early-Career Researchers: Long-Term Outcomes of the Susan G. Komen© Career Catalyst Research Program

Lauren Leslie, Susan G. Komen, Dallas, TX

P5-5-21

Real-world invasive disease-free survival and event composition among patients with HR+/HER2-negative early breast cancer meeting NATALEE eligibility criteria: RELIABLEe study

Laia Joval-Ramentol, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

P5-5-22

Outcomes for breast conservation surgery after neoadjuvant chemotherapy

Likolani Arthurs, NYU Grossman School of Medicine, New York, NY

P5-5-23

Cumulative incidence of CNS metastases among patients with HER2-low metastatic breast cancer receiving trastuzumab deruxtecan

Reshma Mahtani, Wertheim Cancer Institute, Baptist Health South Florida, Miami, FL

P5-5-24

Real-world clinical outcomes following trastuzumab deruxtecan treatment de-escalation in metastatic breast cancer: a single-center retrospective analysis

Ashley C Dunton, Medical College of Wisconsin, Milwaukee, WI

P5-5-25

Body Mass Index ≥25 kg/m² as a Risk Marker for Early Hematologic and Gastrointestinal Toxicity During Sacituzumab Govitecan Therapy in Breast Cancer

Isabella Figueiredo, HCOR, Sao Paulo, Brazil

P5-5-26

Real-world effectiveness and tolerability of the keynote-522 regimen in a predominantly african american cohort with early-stage triple-negative breast cancer

Ami Chitalia, Medstar Georgetown Cancer Institute, Washington, DC

P5-5-27

Impact of COVID-19 Pandemic on Patterns of Practice and Survival Outcomes of Neoadjuvant Systemic Therapy in Breast Cancer

Dileep Ramesh Hoysal, Tata Memorial Centre, Mumbai, India

P5-5-28

When pathologists disagree: Inter-observer variability in immunohistochemistry and the robustness of surrogate subtyping in a large real-world invasive breast cancer cohort

Enrique Alanya, Edgardo Rebagliati Martins Hospital, Lima, Peru

P5-5-29

Association of COVID-19 Infection With Survival and Metastatic Outcomes in HER2-Negative Breast Cancer: A Propensity-Matched Analysis

Anna Homeniuk, UPMC Central PA, Harrisburg, PA

P5-5-30

Determinants of Survival in Metastatic Breast Cancer in a Resource-Restricted Setting: A Real-World Analysis

Hikmat Abdel-Razeq, King Hussein Cancer Center, Amman, Jordan

P5-6-01

Real-world clinical outcomes in metastatic breast cancer harboring AKT mutations

Alexandre Peinoit, Institut de Cancérologie de l'Ouest, Saint-Herblain, France

P5-6-02

From Actionable Alterations to Matched Therapy: Nationwide Outcomes of Comprehensive Genomic Profiling in Metastatic Breast Cancer

Dora Cerina Pavlinovic, University Hospital Split, Split, Croatia

P5-6-03

Real-world effectiveness and safety of olaparib in patients with germline BRCA-mutated HER2-negative advanced breast cancer: finding from the JBCRG-C09 OPTIMAL study

Hidetoshi Kawaguchi, Nagoya City University East Medical Center, Nagoya, Japan

P5-6-04

Sequencing CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer: First- vs Second-Line Use in a Portuguese Multicenter Real-World Cohort

Maria Inês Teodoro, Faculty of Pharmacy University of Lisbon, Lisbon, Portugal

P5-6-05

Clinical Outcomes and Treatment Feasibility of Dose-Dense Versus Conventional Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer: A Multicenter Real-World Cohort Study

Kaori Terata, Nagoya City University, Nagoya, Japan

P5-6-06

Real-world outcomes of sequencing antibody-drug conjugates  datopotamab  deruxtecan,  trastuzumab  deruxtecan,  and  sacituzumab  govitecan  in metastatic HR+/HER2-  BC and TNBC

Sabina V Yampolsky, Mayo Clinic, Rochester, MN

P5-6-07

Eligibility for Adjuvant CDK4/6 Inhibitors in HR+/HER2- Early Breast Cancer: A Real-World Cohort from Mexico

Juan Carlos Núñez-Hernández, Instituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán”, Mexico City, Mexico

P5-6-08

Real-world analysis of inavolisib-associated hyperglycemia in chinese patients with advanced breast cancer: incidence, severity, management and time to recovery

Chao Li, Beijing Hospital, Beijing, China

P5-6-09

Understanding Invasive Lobular Carcinoma: Distinctive Features, Imaging Limitations and Treatment Patterns in Clinical Practice

Inés Marrodán Ciordia, Hospital Universitario Cruces, Bilbao, Spain

P5-6-10

Doubly Robust IPTW Cox Analysis Evaluating the Real-World Impact of Prior CDK4/6 Inhibitor Exposure on T-DXd Efficacy and Durability in Heavily Pretreated Advanced Breast Cancer

Ying Han, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China

P5-6-11

Overweight and Obesity Mask Nutritional Risk and Sarcopenia in Breast Cancer Patients: Impact of a Modified NutriScore in a Real-World Mexican Cohort

Saul Campos Gomez, Centro Oncológico Estatal ISSEMyM, Toluca de Lerdo, Mexico

P5-6-12

Co-occurring ESR1 and PI3K/AKT pathway alterations in hormone receptor-positive metastatic breast cancer: a single-institution real-world series

Abhinav A Vayal Veettil, Cleveland Clinic Foundation, Cleveland, OH

P5-6-13

Real-world effectiveness, safety, and survival outcomes of trastuzumab deruxtecan in her2-positive and her2-low breast cancer: first chilean experiencereal-world effectiveness, safety, and survival outcomes of trastuzumab deruxtecan in her2-positive and her2-low breast cancer: first chilean experience

Claudio Salas, Clinica Alemana de Santiago, Santiago, Chile

P5-6-14

Reimagining Approaches to Capturing Patient Perspectives: Lessons Learned From a Prospective Study in Patients With Pretreated Metastatic Breast Cancer

Jeanna Wallenta Law, Gilead Sciences, Inc., Foster City, CA

P5-6-15

Real-world efficacy and safety of TS-1 plus endocrine therapy in hormone receptor-positive, her2-negative early-stage breast cancer: a multicenter Taiwanese experience including NATALEE-eligible population

Cheng-Chung Chang, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan

P5-6-16

Real-world treatment delivery, toxicity, and outcomes with the keynote-522 regimen in early-stage triple-negative breast cancer

Stephanie Adel Haddad, UT Health San Antonio/Mays Cancer Center, San Antonio, TX

P5-6-17

Anthracycline-free treatment in HER2-positive early breast cancer: a retrospective population-based cohort study

Stephan Seitz, University Medical Center Regensburg, Regensburg, Germany

P5-6-18

Pyrotinib-based neoadjuvant therapy in her2-positive breast cancer: a real-world study from a chinese multicenter cohort

Yu Yang, zhejiang cancer hospital, hangzhou, China

P5-6-19

Nodal Burden Modifies the Prognostic Impact of Lobular Histology in Estrogen Receptor-Positive Grade 1-2 Breast Cancer: A SEER Analysis

Akshat Patel, Dana-Farber Cancer Institute, Boston, MA

P5-6-20

Optimizing abemaciclib therapy: dose modifications and treatment outcomes

Stephanie G White, Vanderbilt Health, Nashville, TN

P5-6-21

Efficacy and safety of trastuzumab deruxtecan dosereductionin metastatic breast cancer: a real-world, multicentre, retrospective cohort study

Zheng Lv, The First Affiliated Hospital of Jilin University, changchun, China

P5-6-22

Real-world evidence on treatment patterns and clinical outcomes in patients with metastatic breast cancer in Mexico: a multicenter cohort study

Cynthia Villarreal-Garza, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico

P5-6-23

Age-specific trends in breast cancer hospitalizations, metastatic disease, and inpatient mortality in the united states, 2016-2023

Charles Abraham Joseph Larson, Trinity School of Medicine, Warner Robins, GA

P5-4-01

Fragmentomics Enables Actionable Breast Cancer Subtyping on a Commercial Liquid Biopsy Assay

James M. Davison, GeneCentric, Durham, NC

P5-4-02

A closer look at Kaplan-Meier curves: how curve shape reveals previously hidden insights into sub-populations and dynamics of response to therapy

Daniel Cook, SimBioSys, Inc., Chicaco, IL

P5-4-03

Stromal tumor-infiltrating lymphocytes (sTILs) in breast cancer diagnosed during pregnancy (PrBC): a matched case-control study

Marta Perachino, Vall d'Hebron Institute of Oncology (VHIO), Barcellona, Spain

P5-4-04

Impact of 21-Gene Testing on Adjuvant Chemotherapy Treatment Decisions: A Meta-Analysis

Antonio Llombart-Cussac, Hospital Arnau Vilanova, Valencia, Spain

P5-4-05

Association of UGT1A1 genotype with toxicity-related healthcare costs in patients with breast cancer treated with sacituzumab govitecan

Isabel Blancas, San Cecilio University Hospital, Granada, Spain, Granada, Spain

P5-4-06

Multicenter real-world clinical experience with an ultrasensitive structural variant-based tumor-informed ctDNA assay for molecular residual disease detection in early breast cancer

Daniel Sumarriva, SAGA Diagnostics Inc, Morrisville, NC

P5-4-07

P.p1 {margin: 0.0px 0.0px 0.0px 0.0px; font: 11.0px arial; color: #000000} an estrogenic-adrenergic transcriptional signature is associated with poor survival in luminal a breast cancer breast cancer

marc lippman, georgetown university, Washington, DC

P5-4-08

Feasibility of Genome-wide Mapping of 5-methylcytosines to Evaluate Epigenetic Biomarkers in Breast Cancer

Nan Chen, University of Chicago, Chicago, IL

P5-4-09

Risk of Second Primary Ovarian Cancer After Breast Cancer: A Population-Based Registry Study with Implications for Germline Genetic Testing

Vinay H Deshmane, Indian Cancer Society, Mumbai, India

P5-4-10

Apobec3 expression associates with improved patient outcomes independent of treatment arm or subtype in i-spy2

Joel Pardo, University of Minnesota, Minneapolis, MN

P5-4-11

Recurrence by histologic type (lobular, mixed, or no special type) in context of genomic risk in the Carolina Breast Cancer Study

Elizabeth B Haas, University of North Carolina at Chapel Hill, Chapel Hill, NC

P5-4-12

Quantitative HER2/ERBB2 expression in QuantifyHER (TBCRC 066), a prospective cohort study of patients with metastatic HER2 low/ultralow breast cancer initiating Trastuzumab Deruxtecan: a pre-planned interim analysis

Eleanor Taranto, University of Pennsylvania, Philadelphia, PA

P5-4-13

A comprehensive tumor marker database and associated biological specimens for discovery of cancer diagnostics, prognostics and molecular targets for novel therapeutics

James L. Wittliff, University of Louisville, Louisville, KY

P5-4-14

Her2-low versus her2-zero status and the 21-gene recurrence score in hormone receptor-positive, node-negative early breast cancer

Hazha Abdulla Mohammed, Hiwa Cancer Hospital, Sulaimaniyah, Iraq

P5-4-15

Complementing tissue biopsy: a combined cellular and cell-free liquid biopsy workflow reveals heterogeneity in metastatic breast cancer

Roberta Carbone, Tethis S.p.A., Milano, Italy

P5-4-16

Whole-genome sequencing reveals distinctive chromosome 17 copy number and structural variant landscapes in breast cancer tissue samples

Brittany Mineo, Tempus AI, Chicago, IL

P5-4-17

Platelet mRNA expression profiling as a dynamic biomarker for predicting pathological complete response to neoadjuvant therapy in early-stage breast cancer.

IZASKUN URDANIBIA, IRBLleida, Lleida, Spain

P5-4-18

Frequency and Prognostic Significance of Homozygous Gene Losses in HR+/HER2- Breast Cancer

Elena Shagisultanova, University of Colorado, Aurora, CO

P5-4-19

Liquid Biopsy for the Evaluation of Syndecan-1 Expression Across Different Breast Cancer Subtypes

Daniel Luiz Gimenes, Beneficência Portuguesa de São Paulo, Sao Paulo, Brazil

P5-4-20

Dickkopf-1as a key driver of cancer stemness and a potential therapeutic vulnerability in aggressive breast cancer.

Mohd Mughees, UT MD Anderson Cancer Center, Houston, TX

P5-4-21

A patient-derived biofluid-based primary culture platform for functional precision medicine in breast cancer

Gou Watanabe, Tohoku Medical and Pharmaceutical Univ., Sendai, Japan

P5-4-22

Epigenetic age acceleration in early-onset breast cancer: A multi-clock DNA methylation analysis from the Long Island Breast Cancer Study

Ryan Mai Kao, Columbia University, New York, NY

P5-4-23

Mtap loss in metaplastic breast cancer: clinical characteristics and genomic landscape

Mariana Carvalho Gouveia, Yale Cancer Center, Yale School of Medicine, New Haven, CT

P5-4-24

Identifying Clinicopathologic Features Associated with BCI Minimal Risk of Recurrence in Patients with ER+ Early-Stage Invasive Breast Cancer

Nimmi Singh Kapoor, University of California Los Angeles, Los Angeles, CA

P5-4-25

Targeting FAK sensitizes triple-negative breast cancer to ferroptosis and potentiates clinically actionable therapy

Chi-Wen Luo, Kaohsiung Medical University Hospital, Kaohsiung city, Taiwan

P5-4-26

Circulating Tumor Cells and HER2 Expression as Prognostic Biomarkers in HR+/HER2- Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitors: A Retrospective Analysis

Valentina Frescura, Weill Cornell Medicine/New York-Presbyterian Hospital, New York, NY

P5-4-27

Her2 expression on circulating tumor cells as a biomarker of outcome in metastatic breast cancer

Fabiana Pratticò, Weill Cornell Medicine/New York-Presbyterian Hospital, New York, NY

P5-4-29

Impact of baseline and end-of-treatment inflammatory/neutritional indices on clinical outcomes of eribulin in HER2-negative advanced breast cancer.

Ryoko Semba, Juntendo University School of Medicine, Tokyo, Japan

P5-4-30

An Estrogen-Independent Proliferative Index (EIPI) Identifies High-Risk Luminal Breast Cancer Beyond the Nottingham Prognostic Index: A METABRIC Analysis

Mehmet Mutlu ÇATLI, Antalya Education and Research Hospital, Antalya, Turkey

P5-7-01

Homologous recombination deficiency predicts pathological complete response in HER2-low early breast cancer.

Chang Gong, Sun Yat-sen Memorial Hospital, Guangzhou, China

P5-7-02

Age-related differences in transcriptomic, molecular, clinical, and treatment characteristics in metastatic breast cancer

Nothando Natasha Mangena, Geisel School of Medicine at Dartmouth, Hanover, NH

P5-7-03

From Epigenetic Rewiring to Clinical Utility: Decoding LncRNA-Chromatin Remodeling Crosstalk in Breast Cancer

Sherihan Galal AbdelHamid, Faculty of Pharmacy Ain Shams University, Cairo, Egypt

P5-7-04

Preclinical evaluation of BRCA1 promoter methylation as a biomarker of PARP inhibitor sensitivity in breast cancer models

Jee Hung Kim, Gangnam Severance Hospital, Yonsei University College of Medicine, SEOUL, Korea, Republic of

P5-7-05

LRRC15-High Triple-Negative Breast Cancer retains a favorable prognosis despite co-occurring PI3K/AKT/mTOR pathway alterations.

Dan Morgenstern-Kaplan, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL

P5-7-07

A novel microenvironment-like biomarker for high-accuracy classification of early-stage breast cancer by liquid histology and multiplex immunofluorescence.

Kathleen Ho, Sonder Research X, North Brunswick, NJ

P5-7-08

Marker-level analysis of circulating epithelial and stemness features in high-risk breast cancer

Diego F Chamorro, University of Pittsburgh Medical Center, Pittsburgh, PA

P5-7-09

Real-world Outcomes and Molecular Landscape of HR+/HER2- Male Breast Cancer Treated with PARP Inhibitors

Dario Trapani, European Institute of Oncology, IRCCS, Milan, Italy

P5-7-10

Single-cell profiling identifies functional ecotypes of metastatic lymph nodes as potential biomarkers for axillary de-escalation after neoadjuvant therapy in breast cancer

Siyan Liu, Peking University People's Hospital; Beijing Key Laboratory of AI-Enabled Data Governance and Precision Medicine for Breast Cancer, Beijing, China

P5-7-11

An exercise-induced muscle secretory gene signature predicts favorable outcome in luminal breast cancers

Otilia Menyhart, Semmelweis University, Budapest, Hungary

P5-7-12

Real-world outcomes and genomic correlates of adc therapy in metastatic breast cancer

Zarina Brune, Dartmouth Hitchcock Medical Center, Lebanon, NH

P5-7-13

Cancer antigen 15-3 secretion phenotype as a biomarker of therapeutic resistance and distinct transcriptional states in metastatic breast cancer

Regina Shrestha, Dartmouth Hitchcock Medical Center, Lebanon, NH

P5-7-14

Association of Oncotype DX Recurrence Score With Clinical Outcomes and Genomic Alterations in Metastatic Breast Cancer

Regina Shrestha, Dartmouth Hitchcock Medical Center, Lebanon, NH

P5-7-15

One mutation is not enough: ESR1 polyclonality reveals the evolutionary depth of endocrine resistance at first-line progression

Lucrezia Raimondi, Ospedale degli Infermi, Ponderano (Biella), Italy

P5-7-16

Real-world recurrence free survival following molecular residual disease testing in stage ii-iii breast cancer using a methylation-based circulating tumor dna assay

Maxwell R Lloyd, Mass General Cancer Center, Boston, MA

P5-7-17

Clinical and Genomic Predictors of Early CDK4/6 Inhibitor Resistance in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer

Caitlin Taylor, Ochsner MD Anderson Cancer Center, New Orleans, LA

P5-7-18

Circulating endotrophin is associated with disease activity in metastatic ER+/HER2− breast cancer

Bethania Santos, University of Texas Southwestern Medical Center, Dallas, TX

P5-7-19

Association of CD47 expression with the 70-gene genomic risk assay, 80-gene molecular subtyping, and clinical outcomes in early breast cancer

Layeequr-Rakhshanda Rahman, Texas Tech University Health Sciences Center, Lubbock, TX

P5-7-20

Single cell analysis of HER2 partial or complete loss of extracellular domain (p95HER2+) in invasive breast cancer is associated with low HER2 FISH copy numbers, ER positive and poorer outcomes after standard of care combined HER2 directed chemotherapy.

Alexander D Borowsky, UCSF, San Francisco, CA

P5-7-21

Breast cancer index testing and clinicopathologic risk assessment: A single-institution real-world experience from the University of Arizona Cancer Center (UACC)

Freya Abraham, University of Arizona College of Medicine – Tucson, Tucson, AZ

P5-7-22

Eno1-mediated ferroptosis resistance is augmented by mutant p53, offering a therapeutic target in triple negative breast cancer.

Yingying Xu, The First Hospital of China Medical University, Shenyang, China

P5-7-23

Longitudinal assessment of PD-L1 expression on tumor tissues and circulating tumor cells (CTCs) of triple-negative breast cancer (TNBC) patients receiving neoadjuvant treatment

Sofia Chatziavraam, University of Crete, Heraklion, Crete, Greece

P5-7-24

Integrated response and prognosis profiling refines recurrence-risk stratification and identifies early triple-negative breast cancer patients for treatment optimization

Barbora Huraiová, MultiplexDX, s.r.o., Bratislava, Slovakia

P5-7-25

Enrichment-free detection and longitudinal characterization of circulating tumor cells (CTCs) and ctc clusters in early breast cancer (eBC): interim results of a prospective pilot study

Lorenzo Foffano, Weill Cornell Medicine, New York, NY

P5-7-27

Association of Circulating Tumor Cells with Cell-Free RNA-Based Detection of HER2 Positivity in Metastatic Breast Cancer

Padma Sri Katikaneni, University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA

P5-7-28

Evaluating MRI radiomics-derived clusters and feature-level associations with computational pathology in TCGA-BRCA

Leyla Ebrahimpour, Memorial Sloan Kettering Cancer Center, New York, NY

P5-7-29

Genomic landscape and clinical utility of next-generation sequencing (NGS) in early breast cancer at time of diagnosis

Sophie Richard, BC Cancer, Vancouver, BC, Canada

P5-8-01

Genomic Alterations Associated with Rapid Progression During CDK4/6 Inhibitor Therapy in Advanced Breast Cancer

Peter Xiong, Dartmouth Hitchcock Medical Center, Lebanon, NH

P5-8-02

Patient-derived organoids capture breast cancer heterogeneity, revealing a BLIS-dominant triple-negative breast cancer (TNBC) subtype

Kyung-Hun Lee, Seoul National University Hospital, Seoul, Korea, Republic of

P5-8-03

Plasma Metabolomic Signatures for Early Detection of Breast and Lung Cancer in Women Aged 25-75: A Combined Cohort Analysis

Jean-Francois Haince, Biomark Diagnostic Solutions Inc., Quebec City, QC, Canada

P5-8-04

Beyond CDK4/6 Inhibition: Abemaciclib as a Metabolic Modulator

Thanh Nga Doan, City of Hope, Duarte, CA

P5-8-05

Evaluation of the Integrin α<sub>v</sub>β<sub>6</sub> targeted theranostic pair [<sup>68</sup>Ga]Ga DOTA-5G and [<sup>177</sup>Lu]Lu DOTA-ABM-5G in patients with metastatic breast cancers.

Julie L Sutcliffe, University of California Davis, Sacramento, CA

P5-8-06

Altered plasma phosphatidylethanolamine and fatty acid profiles differentiate benign breast disease from non metastatic breast cancer

Yara Cristina de Paiva Maia, Federal University of Uberlandia, Uberlândia, Brazil

P5-8-07

Tumoral GLP-1 Receptor Expression Identifies a Subgroup of Breast Cancer Patients with Increased Risk of Early Disease Recurrence

Nina Ditsch, University Augsburg, Augsburg, Germany

P5-8-08

Coxsackievirus and Adenovirus Receptor Expression Supports Evaluation of AdAPT-001 in Invasive Breast Carcinoma

Jaimin R Shah, University of California San Diego, La Jolla, CA

P5-8-09

The prognostic and predictive value of HER2 overexpression in ductal carcinoma in situ (DCIS): a systematic review and meta-analysis

Abhisekh Chatterjee, Imperial College London, London, United Kingdom

P5-8-10

Noninvasive Detection of Glutamine Antagonism-Induced Antitumor Immunity in Triple-Negative Breast Cancer Using CD69 ImmunoPET

Hoon Choi, University of Pennsylvania, Philadelphia, PA

P5-8-11

Serial ctDNA dynamics stratify recurrence risk beyond binary detection in early-stage breast cancer

Oleg Gligich, Mount Sinai Medical Center, Miami Beach, FL

P5-8-12

Single-section 16-plex spatial immunofluorescence profiling of therapeutic targets, proliferative states, and immune architecture in breast cancer

Richard Van Krieken, Navigate BioPharma, Carlsbad, CA

P5-8-13

Single-cell-informed deconvolution identifies a dormant malignant cell fraction associated with overall survival in ER+/HER2− breast cancer

Anshulika Deshmukh, Duke University, Durham, NC

P5-8-14

Baseline Peripheral Blood CD4/CD8 Ratio and Pathologic Response to Neoadjuvant Therapy in Early Breast Cancer: An Intention-to-Treat Analysis of 66 Patients by Molecular Subtype

Diogo Alpuim Costa, Hospital de Cascais, Cascais, Portugal

P5-8-15

Ctdna particle fraction (cpf) tracks neoadjuvant response in breast cancer and reveals threshold-dependent mrd: an ultrasensitive crispr-based (mute-seq) study

Hong-Kyu Kim, Seoul National University College of Medicine, Seoul, Korea, Republic of

P5-10-01

Subtype-specific differences in presentation and survival between de novo metastatic inflammatory and non-inflammatory breast cancer

Jincong Q. Freeman, UChicago Medicine Comprehensive Cancer Center, Chicago, IL

P5-10-02

Clinical and pathologic features of advanced breast cancer (ABC) with chest wall disease (CWD): results from the first multidisciplinary CWD program nationwide

Neelima Vidula, Massachusetts General Hospital, Harvard Medical School, Boston, MA

P5-10-03

Cytomegalovirus gene expression signature & immune microenvironment reprogramming in breast cancer brain metastases

James Sampson, Texas A&M University, Houston, TX

P5-10-04

Single-cell and spatial multi-omics exploration of the autoimmune-like tumor microenvironment in inflammatory breast cancer

Handong Sun, Women's Hospital of Nanjing Medical University, Nanjing, China

P5-10-05

Metronomic capecitabine versus intermittent capecitabine as maintenance therapy following the first-line chemotherapy of capecitabine plus docetaxel in HER2-negative metastatic breast cancer:the randomized noninferiority phase III CAMELLIA trial

Xiuwen Guan, National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

P5-10-06

Biochemical liver recovery with anthracycline-based combination chemotherapy in metastatic breast cancer and tumor-related hepatic dysfunction: predictors of biochemical response

Manuel Alva Bianchi, Hospital Universitario 12 de Octubre, Madrid, Spain

P5-10-07

Age-based comparison of demographic and clinical factors in patients with de novo metastatic breast cancer

Ridwana Islam, UT Southwestern Medical Center, Dallas, TX

P5-10-08

Healthcare Utilization, Symptom Burden, and Disease Characteristics Predict Survival Beyond Comorbidity in Metastatic Breast Cancer

Abbey J Kaler, The University of Texas MD Anderson Cancer Center, Houston, TX

P5-10-09

Clinical outcomes in patients with de novo versus recurrent metastatic breast cancer: a systematic review and meta-analysis

Taiga Komatsu, Mount Sinai Morningside/West, New York, NY

P5-10-10

Biofilm-mediated extracellular matrix remodeling: a potential mechanism promoting breast cancer metastasis through asporin dysregulation

Girdhari Rijal, Tarleton State University, Fort Worth, TX

P5-10-11

Differential Lesion Responses by Metastatic Location in Bria-ABC Metastatic Breast Cancer Trial

Blaise Bayer, BriaCell Therapeutics Corp, Philadelphia, PA

P5-10-12

De novo HR-low/HER2-low metastatic breast cancer: A real-world retrospective study

Chongxi Ren, Hebei Cangzhou Hospital of Integrated Traditional Chinese Medicine and Western Medicine, Cangzhou, China

P5-10-14

Distinct systemic and spatial immune signatures define immune escape and exceptional survival in metastatic breast cancer

Helen Kakkassery, King's College London, London, United Kingdom

P5-10-15

A phase 1/2 trial of tersolisib (ly4064809/stx-478), a pan-mutant-selective pi3kα inhibitor (pi3kαi) in pik3ca-mutant hr+, her2- advanced breast cancer: updated triplet cohort results from pikalo-1

Maxime Brunet, Institut Bergonié, Bordeaux, France

P5-10-16

Real-world effectiveness of T-DXd and clinical impact of central HER2 reassessment in HER2-low mBC: primary results from HALLOW, a large prospective cohort Study

Emi Tokuda, Fukushima Medical University School of Medicine, Fukushima, Japan

P5-10-17

Prognostic impact of molecular subtype in bone-only metastatic breast cancer treated with bone-targeting agents: a bicentric retrospective study

Andy KOUANGA, Louis et Marie Pasteur university, BESANCON, France

P5-10-18

Biomarker Landscape and Its Correlation with Clinicopathological Features in Breast Cancer

Konstantinos Papazisis, European Interbalkan Medical Center, Thessaloniki, Greece

P5-10-19

Baseline ctDNA biomarkers associated with PFS benefit from vepdegestrant, a PROteolysis TArgeting Chimera estrogen receptor (ER) degrader vs fulvestrant in ER+/HER2− advanced breast cancer: exploratory analysis from the phase III VERITAC-2 study

Seth A. Wander, Harvard Medical School, Boston, MA

P5-10-20

Updated Real-World Outcomes of Trastuzumab Deruxtecan with or without Endocrine Therapy in HER2-Low, Hormone Receptor-Positive Metastatic Breast Cancer: A Propensity-Matched Analysis

Michela Palleschi, IRST IRCCS Dino Amadori, Meldola, Italy

P5-10-21

Utilization patterns and survival outcomes of liver-directed therapy in patients with breast cancer liver metastases

Manasa Kotamraju, UT Southwestern Medical Center, Dallas, TX

P5-10-22

Treatment patterns and clinical outcomes of patients with HER2-mutant metastatic breast cancer (mBC): real-world evidence from a large US clinico-genomic database study

Rani Bansal, Duke Cancer Institute, Durham, NC

P5-10-23

Association of Sentinel Lymph Node Extracapsular Extension with Axillary Tumor Burden and Survival Outcomes in Breast Cancer

Beatriz Westphalen Pomianoski, A.C. Camargo Cancer Center, Sao Paulo, Brazil

P5-10-24

Omitting axillary lymph node dissection for sentinel-node macrometastases in a resource limited, post-disaster region: residual nodal disease and the care coordination challenge

Kenji Gonda, Jyoban Hospital of Tokiwa Foundation, Fukushima, Japan

P5-10-25

Real-world (RW) patient characteristics and outcomes of trastuzumab deruxtecan (T-DXd) therapy among patients with hormone receptor-negative (HR-)/HER2-low metastatic breast cancer (mBC) in the United States (US)

Peter A Kaufman, Larner College of Medicine University of Vermont, Burlington, VT

P5-10-26

Concurrent KRAS Genomic Alterations and MTAP Loss in Advanced Breast Cancer: Prevalence, Clinical Characteristics, and Genomic Landscape

Nicole Casasanta, Yale Cancer Center, Yale School of Medicine, New Haven, CT

P5-10-27

Phase II Study of Olaparib Maintenance Therapy in Patients with Metastatic Breast Cancer Following Platinum-Based Chemotherapy

Po-Han Lin, National Taiwan University Hospital, Taipei City, Taiwan

P5-10-28

Association of Comorbidity Burden and Individual Comorbid Conditions with Survival in Metastatic Breast Cancer

Abbey J Kaler, The University of Texas MD Anderson Cancer Center, Houston, TX

P5-10-29

Novel assay to detect and characterize circulating tumor cells (CTCs) in the cerebrospinal fluid (CSF) of patients with metastatic breast cancer (MBC) and leptomeningeal disease (LMD)

Laura A Huppert, University of California San Francisco, San Francisco, CA

P5-13-01

Impact of Body Mass Index and age on Trastuzumab-Deruxtecan toxicity in advanced breast cancer: a subanalysis from the PROCURE study

Rodrigo Sanchez-Bayona, Hospital Universitario 12 de Octubre. Instituto de Investigacion Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain

P5-13-02

Spatial immune hotspots reveal divergent roles of t cells and b cells in inflammatory breast cancer outcomes

Jinming Yang, Duke University, Durham, NC

P5-13-03

Metastatic patterns, overall survival and prognostic factors in metastatic invasive lobular breast cancer: Real-world evidence from a Peruvian public cancer center

Jorge Luis Sanchez Alarcon, Instituto Nacional de Enfermedades Neoplásicas (INEN), Lima, Peru

P5-13-04

Improving Identification and Treatment of HER2-Low and HER2-Ultralow Metastatic Breast Cancer Through Integrated Continuing Medical Education and Quality Improvement

Reshma L Mahtani, Baptist Health, Plantation, FL

P5-13-05

The Effect of Breast Surgery on Survival in Patients with Isolated Distant Lymph Node Metastatic Breast Carcinoma

Izzet Dogan, Acibadem Healthcare Group, Istanbul, Turkey

P5-13-06

Updated Overall Survival and HER2 Subgroup Analysis of Disitamab Vedotin in HER2-Expressing Metastatic Breast Cancer With PI3K/AKT/mTOR Pathway Activation: A Prospective Multicenter Phase II Study

Yun Wu, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

P5-13-07

Clinical and Molecular Characteristics of Exceptional Responders With Metastatic Breast Cancer

Girahnaz Baloch, Cleveland Clinic, Cleveland, OH

P5-13-08

Efficacy and safety data of KH815 (dual-payload TROP2 targeted antibody-drug conjugate [ADC]) in advanced/metastatic breast cancer previously treated or untreated with topoisomerase 1 inhibitor based ADCs: Results from the first-in-human study

Fei Ma, Chinese Academy of Medical Sciences and Peking Union Medical College – National Cancer Center, Cancer Hospital, Beijing, China

P5-13-09

Decision-making in HER2-low and HER2-ultralow metastatic breast cancer: a mixed-methods physician survey

Adam M Brufsky, University of Pittsburgh, Pittsburgh, PA

P5-13-10

Association of Bone-Directed Radiation Therapy With Overall Survival in De Novo Metastatic Breast Cancer: A National Cancer Database Analysis

Kaidi Wang, The Ohio State University Stefanie Spielman Comprehensive Breast Center, Columbus, OH

P5-13-11

Exceptional Responders and Long-Term Survival in Metastatic Breast Cancer: A Real-World Subtype-Specific Analysis

Megumi Miyamoto, Nagoya City University Graduate School of Medical Sciences, Mizuho-ku, Nagoya, Aichi, Japan

P5-13-12

Updated Real-World Outcomes of Cyclin-Dependent Kinase 4/6 Inhibitors in Male Patients with Metastatic Breast Cancer: A Propensity-Matched Analysis

Simone Sabbioni, IRCCS Istituto Romagnolo per lo studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy

P5-13-13

Parp inhibitors versus physician’s choice chemotherapy in brca-mutated her2-negative metastatic breast cancer: a systematic review and meta-analysis

Joao Paulo Gonzaga Faria, Oncoclínicas, Belo Horizonte, Brazil

P5-13-14

Intracranial activity of trastuzumab deruxtecan in HER2-low breast cancer with brain metastases: an updated systematic review and meta-analysis

Shreya Ghanshyam Patel, Lakeland Regional Health, Lakeland, FL

P5-13-15

Survival outcomes in inflammatory breast cancer with isolated contralateral axillary metastasis and stage III IBC

Megan McClanahan, UT MD Anderson Cancer Center, Houston, TX

P5-13-16

Clinical and Demographic Characteristics of Metastatic Breast Cancer Patients with Isolated CNS versus CNS and Extracranial Metastases

Deanna Blansky, Yale Cancer Center, Yale School of Medicine, New Haven, CT

P5-13-17

Impact Assessment of Serial CTC Results in Prospective ACT-MBC study in Metastatic Lobular Breast Cancer Patients

Femke de Snoo, Medex15, Amsterdam, Netherlands

P5-13-18

Circulating tumor cells (CTCs) and CTC clusters characterization of invasive lobular carcinoma (ILC) in patients with metastatic breast cancer (MBC): a comparison with ductal histology

Eleonora Nicolo, Weill Cornell Medicine, New York, NY

P5-13-19

Clinical Outcomes Associated with Bone-Modifying Agent Dosing Frequency in Patients with Metastatic Breast Cancer: A Retrospective Cohort Study

Sailaja Kamaraju, Medical College of Wisconsin, Milwaukee, WI

P5-13-20

Prior Checkpoint Inhibitor Exposure and Clinical Outcomes in Heavily Pretreated Metastatic Breast Cancer

Blaise Bayer, BriaCell Therapeutics Corp, Philadelphia, PA

P5-13-21

Clinical Characteristics of Long-Term Survivors with De Novo Metastatic Breast Cancer: A Retrospective Cohort Study

Kimberly Boldig, Henry Ford Health, Detroit, MI

P5-13-22

Progression-free and overall survival in patients with de novo stage IV breast cancer in the era of modern therapy: A population based study from British Columbia (BC)

Sahej Dhak, University of British Columbia, Vancouver, BC, Canada

P5-13-23

Emerging HER2 classifications: implementation of HER2-low and HER2-ultralow testing and treatment across academic and community settings

Peter A Kaufman, University of Vermont Cancer Center, Burlington, VT

P5-13-24

Real-world use of antibody-drug conjugates in metastatic breast cancer in a Brazilian cohort

Wesley Antônio Lopes de Lima, Instituto D'Or de Ensino e Pesquisa (IDOR), São Paulo, Brazil

P5-13-25

Trimodal Therapy in Stage IV Breast Cancer Patients is Associated with Improved Overall Survival

Magnolia Donaji Garcia-Mendoza, National Cancer Institute of Mexico, Mexico City, Mexico

P5-13-26

Trial in Progress Abstract: MELODY – Mapping the Enhanced Landscape of advanced breast cancer fOr DYnamic treatment approaches

Emer Lynch, Cork University Hospital / University College Cork Cancer Centre, Cork, Ireland

P5-13-27

Real-world efficacy of antibody drug conjugates in metastatic metaplastic breast cancer

Xiaojie Zhang, University of California San Diego, La Jolla, CA

P5-13-28

Mircrorna-30b suppresses inflammatory breast cancer progression through modulation of the marcks signaling axis

Marwa Manai, Pasteur Institute of Tunis, Tunis, Tunisia

P5-6-24

Feasibility and relevance of a breast cancer PRO registry

Kayla Stewart, Health Catalyst, South Jordan, UT

P5-13-29

First disclosure of efficacy and safety of beruzatatug pelitecan (Beru-Pel; YL202/BNT326; a HER3 antibody-drug conjugate [ADC]) in patients with unresectable locally advanced or metastatic triple-negative breast cancer: Phase 2 trial results

Jian Zhang, Phase I Unit, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, China

P5-6-25

Real-world dose-escalated abemaciclib in HR+/HER2− advanced breast cancer: a brazilian single-center experience

Wesley Antônio Lopes de Lima, Instituto D’Or de Pesquisa e Ensino, São Paulo, Brazil

P5-6-26

Metastatic Invasive Lobular Breast Cancer: A Single-Center Real-World Analysis of Disease Patterns, Treatment Sequencing and Outcomes

Alice Figueiredo, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal

P5-6-27

Clinical T category does not predict nodal burden in elderly cN0 breast cancer: a real-world cohort study.

Lyudmila Zhukova, The Loginov Moscow Clinical Scientific Center, Moscow, Russian Federation

P5-6-30

Real-world ultrasensitive ctdna profiling reveals genomic and prognostic features in hr-positive, her2-negative advanced breast cancer

Haoran Tang, Huidu Shanghai Medical Sciences Ltd., Shanghai, China